Maxim Group analyst Jason McCarthy maintained a Buy rating on IntelGenx Technologies (IGXT) today and set a price target of $2. The company’s shares opened today at $0.65, close to its 52-week low of $0.43.
McCarthy wrote:
“IntelGenx reported FY18 results with $1.8M in revenue and a net loss of $10.6M. The company ended the period with $11M in cash on the balance sheet, runway into 1H20.”
According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -3.9% and a 34.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Actinium Pharmaceuticals.
IntelGenx Technologies has an analyst consensus of Moderate Buy, with a price target consensus of $2.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.83 and a one-year low of $0.43. Currently, IntelGenx Technologies has an average volume of 312K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
IntelGenx Technologies Corp. engages in the development of novel oral immediate-release and controlled-release products for the pharmaceutical market. Its products include rizaport, tadalafil, loxapine, and montelukast.
